Evidence map›Paper›PMID 39812745›Full record

ReviewMedical oncology (Northwood, London, England)2025

Emerging nanoplatforms towards microenvironment-responsive glioma therapy.

Nigam Sekhar Tripathy, Liza Sahoo, Safal Paikray, Fahima Dilnawaz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nigam Sekhar Tripathy *School of Biotechnology, Centurion University of Technology and Management, Jatni, Bhubaneswar, Odisha, 752050, India.
Liza Sahoo *School of Biotechnology, Centurion University of Technology and Management, Jatni, Bhubaneswar, Odisha, 752050, India.
Safal PaikraySchool of Biotechnology, Centurion University of Technology and Management, Jatni, Bhubaneswar, Odisha, 752050, India.
Fahima DilnawazSchool of Biotechnology, Centurion University of Technology and Management, Jatni, Bhubaneswar, Odisha, 752050, India. fahimadilnawaz@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas are aggressive intracranial tumors of the central nervous system with a poor prognosis, high risk of recurrence, and low survival rates. Radiation, surgery, and chemotherapy are traditional cancer therapies. It is very challenging to accurately image and differentiate the malignancy grade of gliomas due to their heterogeneous and infiltrating nature and the obstruction of the blood-brain barrier. Imaging plays a crucial role in gliomas which significantly plays an important role in the accuracy of the diagnosis followed by any subsequent surgery or therapy. Other diagnostic methods (such as biopsies or surgery) are often very invasive. Preoperative imaging and intraoperative image-guided surgery perform the most significant safe resection. In recent years, the rapid growth of nanotechnology has opened up new avenues for glioma diagnosis and treatment. For better therapeutic efficacy, developing microenvironment-responsive nanoplatforms, including novel nanotherapeutic platforms of sonodynamic therapy, photodynamic therapy, and photothermal treatments, are employed for improved patient survival and better clinical control outcome. In this review recent advancement of multifunctional nanoplatforms leading toward treatment of glioma is discussed.

Indexed as

Brain NeoplasmsGliomaNanoparticlesTumor MicroenvironmentAnimalsHumansNanotechnologyPhotochemotherapyGliomaPhotodynamic therapyPhotothermal therapyReactive oxygen speciesSonodynamic therapyTumor microenvironment

Identifiers

PMID39812745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.